Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 7, Issue 3, Pages 281-291Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2014.893819
Keywords
bazedoxifene; estrogen; menopause; osteoporosis; vasomotor symptoms
Categories
Funding
- Amgen
- Merck
- Eli Lilly
- Pfizer
Ask authors/readers for more resources
Menopausal therapy with a tissue selective estrogen complex combines estrogens with a selective estrogen receptor modulator, with the goal of blending the desirable effects of estrogens on menopausal symptoms and bone with the tissue selective properties of a selective estrogen receptor modulator. The first tissue selective estrogen complex to receive regulatory approval is a combination of conjugated estrogens (CE) with bazedoxifene (BZA). Clinical trials with CE/BZA in postmenopausal women have shown improvement in vasomotor symptoms, vulvo-vaginal atrophy, and bone mineral density, without stimulation of the endometrium or breast tissue, with a generally favorable safety and tolerability profile. CE/BZA represents a new approach to the management of menopausal symptoms in women with a uterus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available